IncRNA and mRNA sequencing of the left testis in experimental varicocele rats treated with *Morinda officinalis* polysaccharide

LIHONG ZHANG1-3, XIAOZHEN ZHAO1-3 and WEI WANG1-3

1Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Fujian Medical University; 2Key Laboratory of Aging and Neurodegenerative Disease, School of Basic Medical Sciences, Fujian Medical University; 3Laboratory of Clinical Applied Anatomy, Fujian Medical University, Fuzhou, Fujian 350108, P.R. China

Received May 20, 2020; Accepted July 6, 2021

DOI: 10.3892/etm.2021.10570

**Abstract.** Varicocele is a common disease of the male reproductive system. *Morinda (M.) officinalis* is a Chinese herbal medicine, whose main bioactive component *M. officinalis* polysaccharide (MOP) is believed to have a therapeutic effect on varicocele; however, the underlying molecular mechanisms of this effect are poorly understood. In the present study, 24 rats were randomly divided into three groups: i) Control group; ii) experimental varicocele group; and iii) 300 mg/kg MOP administration group. Analysis of mRNA and long non-coding RNA (IncRNA) expression in rat left testicular tissue was performed. The results suggested that a total of 144 mRNAs and 63 IncRNAs, 63 mRNAs and 148 IncRNAs, and 173 mRNAs and 54 IncRNAs were differentially expressed between the varicocele non-treatment and control groups, the varicocele treatment and varicocele non-treatment groups, and the varicocele treatment and control groups, respectively. Following validation by reverse transcription-quantitative PCR, the Yip1 domain family member 7 (*YIPF7*) gene was identified as a key mediator of varicocele pathogenesis and repair effect of MOP. Additionally, genes such as purinergic receptor P2X 4 (*P2RX4*), transmembrane protein 225B (*TMEM255B*) and Wnt family member 9B (*WNT9B*) were confirmed to be differentially expressed between the varicocele non-treatment and control groups. We hypothesize that *TMEM255B* could be a potential novel diagnostic biomarker for varicocele; *WNT9B* and *P2RX4* likely play notable roles in the pathophysiology of the disease through the Wnt signaling pathway and regulation of transmembrane ion channels, respectively. In summary, the present study delineated the molecular mechanisms underlying varicocele pathogenesis and the therapeutic effect of MOP, identified a potential novel diagnostic marker and therapeutic target for varicocele, and provided feasible directions for further studies in the future.

**Introduction**

Varicocele, an abnormal varix of the pampiniform plexus vein, is the most common cause of male infertility. The global incidence of varicocele is 15-20% in the general population and ~40% in patients who are infertile (1-4); this may have a negative impact on human evolution. For spermatogenesis to occur, the testis must descend into the scrotum during the embryonic period to provide proper the conditions of a reductive system. If the valves inside these veins fail, gravity can make the blood pool inside the testicle, eventually leading to enlargement of the veins and formation of a varicocele (7). The upright human posture requires spermatic veins to work against gravity to return deoxygenated blood back to the heart (6). If the valves inside these veins fail, gravity can make the blood pool inside the testicle, eventually leading to enlargement of the veins and formation of a varicocele (7). In ~90% of cases, the disease occurs on the left side, due to the longer left testicular vein, hemodynamics and higher incidence of abnormal venous valves (8,9). Effective therapies for varicocele have yet to be determined (8,10-12). The experimental rat varicocele model, first established in 1981 (13) by partly ligating the left renal vein, is widely used to investigate the pathophysiology, diagnosis and treatment of the disease. Researchers have shown that the following mechanisms contribute to the pathogenesis of varicocele: i) Neuroendocrine system dysfunction; ii) hypoxia; iii) accumulation of metabolites and toxicants; iv) oxidative stress; v) disruption of the blood-testis barrier (BTB); and vi) cell damage resulting from increased testicular temperature (14,15).

In China, *Morinda officinalis* F.C.How grows in the Guangdong, Guangxi and Fujian provinces. The roots of *M. officinalis* are used in a Chinese herbal medicine known as Bajitian; it has a long history of use for the improvement of
male sexual function and the treatment of male reproductive system defects in China (16). *M. officinalis* polysaccharide (MOP) is one of the main active components of *M. officinalis*. Our previous research found that MOP can repair varicocele-induced damage to the male rat reproductive system by promoting spermatogenesis, reconstructing the BTB, increasing the expression of tight junction (TJ) proteins and restoring hormonal balance, with 300 mg/kg being the most effective dosage (17). However, the molecular mechanisms underlying the pathophysiology of varicocele and the physiological functions and therapeutic effects of MOP in varicocele are yet to be explored in detail.

Advances in high-throughput RNA sequencing (RNA-Seq) technology and bioinformatics analysis methods have enabled researchers to gain insight into the nature of diseases at the RNA level by studying the dynamics of mRNA, microRNA and long non-coding RNA (lncRNA) (18) expression levels. According to previous research, lncRNAs, which are >200 nucleotides long and found in multiple organisms (19), play notable roles at almost every step of gene expression and take part in various disease processes (20); for example, in Parkinson's disease (21), leukemia (22), diabetes (23), cardiovascular disease (24), colon cancer (25,26), lung cancer (27) and prostate cancer (28). Due to their diverse bioactivities, lncRNAs are regarded as potential targets for the diagnosis and treatment of varicocele.

In the present study, rats with surgically induced varicocele were treated with either saline or 300 mg/kg MOP by gavage. Identification of differentially expressed (DE) mRNAs and lncRNAs in rat left testicular tissue was conducted by RNA-Seq, and the results were verified by reverse transcription-quantitative PCR (RT-qPCR). Bioinformatics resources, such as Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and co-expression network analysis, were utilized to explore the mechanisms underlying varicocele pathophysiology and the therapeutic effect of MOP, in addition to the interactions between DE mRNAs and lncRNAs in varicocele. The aim of the current study was to identify novel targets and methods for varicocele diagnosis and therapy, and establish a theoretical basis for the use of MOP in clinical practice.

### Materials and methods

**Extraction of MOP.** The plant *M. officinalis* used in the present study was grown (via artificial cultivation) in the Nanjing county of Fujian province in China. MOP was extracted from dried root according to a previously described protocol (17,29,30). In brief, after being ground, the dried root was boiled in ethyl alcohol to remove oligosaccharides and was boiled in deionized water and precipitated with 30% alcohol; thereafter, Sevag reagent (Sinopharm Chemical Reagent Co., Ltd) was added to remove the protein.

**Experimental design.** Male, 6- to 7-week-old Sprague-Dawley rats, weighing 200±10 g, were purchased from and kept in The Laboratory Animal Center of Fujian Medical University (Fuzhou, China). All rats were housed in normal atmosphere (N₂, 78%; O₂, 21%; CO₂, 0.03%) and specific pathogen-free controlled environmental conditions, with a temperature of ~23°C, a 12-h day/night cycle, a humidity of 40-70% and free access to standard rat food and water. All procedures conformed to the Guidelines for the Care and Use of Laboratory Animals established by Fujian Medical University. The study was approved by The Animal Approval Committee of Fujian Medical University (approval no. SYXK-2012-0001).

A total of 24 rats were randomly divided into three equal groups: Control group, varicocele non-treatment group (VC) and varicocele treatment group (VC + MOP). Induction of varicocele was attempted by partial ligation of the left renal vein under anesthesia using 30 mg/kg sodium pentobarbital by intraperitoneal injection (31). Control rats underwent the same operation without the partial ligation, and were fed a conventional diet for 12 weeks. Subsequently, 8 weeks post-surgery, rats in the VC and VC+MOP groups were given a daily oral gavage of 2 ml normal saline or 300 mg/kg MOP, respectively, for 4 weeks; rats in the Control group were given nothing except conventional diet. The rats (weight, 500±25 g) were sacrificed by cervical dislocation after being anesthetized using 30 mg/kg sodium pentobarbital by intraperitoneal injection to collect left testicular tissue, which was immediately placed in liquid nitrogen. Varicocele rats in which vascular dilation did not occur or left kidney atrophy occurred were excluded from the follow-up experiment.

**mRNA and lncRNA sequencing analysis.** RNA-Seq analysis was performed by Kangchen BioTech Co., Ltd. The process used was divided into three parts: i) Extraction of total RNA from rat left testicular tissue; ii) construction of a cDNA library; and iii) RNA sequencing.

In brief, total RNAs were extracted using TRIzol® Reagent (Takara Bio Europe SAS) according to the manufacturer's instructions, followed by purification by Ribo-Zero™ Magnetic Gold Kit (Human/Mouse/Rat) (cat. no. MRZG12324; Epicentre, Illumina, Inc.). The quantity, integrity and concentration of the extracted RNAs were verified by 1% agarose gel electrophoresis and NanoDrop ND-1000 spectrophotometry (Thermo Fisher Scientific, Inc.). For library preparation, the KAPA Stranded RNA-Seq Library Prep kit (cat. no. KK8401; Illumina, Inc.) was used (paired-ended sequencing: 500 bp), with 1-2 µg of sample RNA. The established libraries were examined using an Agilent 2100 Bioanalyzer G2938C (Agilent Technologies, Inc.) and quantified by RT-qPCR. The samples were denatured to single-stranded DNA with 0.1 M NaOH (final density, 8 pM; concentrations measured by RT-qPCR) and amplified using TrueSeqSR Cluster Kit v3-cBot-HS (cat. no. GD-401-3001; Illumina, Inc.). The libraries were pooled and sequenced on the Illumina HiSeq 4000 system (Illumina, Inc.) using 150 cycles of paired-end sequencing.

The quality of the raw sequencing data was assessed using FastQC software v0.11.7 (http://www.bioinformatics. babraham.ac.uk/projects/fastqc/), before the adapter sequences and poor quality bases were trimmed from the reads using the Cutadapt software v1.17 (http://dx.doi.org/10.14806/ej.17.1.200) (32). The Hisat2 software v2.0.4 (http://ccb.jlu.edu.cn/software/hisat2) and StringTie software v1.2.2 (http://ccb.jlu.edu.cn/software/stringtie) (33) were used to calculate fragments per kilobase of transcript per million mapped reads (FPKM) values, which represented the final expression levels of the genes. Differential gene expression
RT-qPCR. To confirm the results of RNA-Seq, specific DE patterns were validated by RT-qPCR, with three biological replicates for each group. TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) was used to extract the total RNAs from rat testicular tissue, according to the manufacturer’s instructions. cDNA was synthesized using 3 μg total RNAs, SuperScript III reverse transcriptase (Invitrogen; Thermo Fisher Scientific, Inc.), 5X reverse transcription buffer solution (Invitrogen; Thermo Fisher Scientific, Inc.), and the GeneAmp PCR 9700 System (50°C for 60 min, 70°C for 15 min and stored at 4°C for infinite time; Applied Biosystems; Thermo Fisher Scientific, Inc.). The RT-qPCR analysis was performed using the SYBR®-Green Real-time PCR Master mix (Arraystar, Inc.) and ViiA™ 7 Real-time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.), with three technical replicates set for each sample. The thermocycling conditions were as follows: 95°C for 10 min; 95°C for 10 sec, then 60°C for 1 min (40 cycles); 95°C for 10 sec; 60°C for 1 min; and 95°C for 15 sec. The primers were designed and purchased from Kangchen BioTech Co., Ltd. The primer sequences are shown in Table I. The relative expression of each gene was quantified by comparing its Cq value (2⁻ΔΔCq method) with that of the housekeeping gene, β-actin (34).

Statistical analyses. RNA-Seq and RT-qPCR were performed in three independent biological replicates for each group. Only genes with an absolute fold-change >1.2 and P-value ≤0.05 were considered to be differentially expressed between the groups. The data were analyzed in SPSS v21.0 (IBM Corp.), and the results are presented as the mean ± standard deviation. Pearson’s correlation was used in scatter plot of DE genes. One-way ANOVA was used to compare gene expression levels between two groups, and P≤0.05 was considered to indicate a statistically significant difference.

Bioinformatic analyses. GO classification and KEGG pathway enrichment analyses were performed using the website of Gene Ontology Resource (http://www.geneontology.org) and KEGG pathway database (https://www.kegg.jp/kegg/pathway.html) respectively. The co-expression of DE mRNA (coding genes) and lncRNA (non-coding genes) networks were visualized using Cytoscape v2.8.3 (http://cytoscape.org). The present study data were uploaded to the Gene Expression Omnibus (GEO) website (https://www.ncbi.nlm.nih.gov/geo/; accession no. GSE139447; secure token: sfaxocskhpoxni).

Results

Identification of DE mRNAs and lncRNAs. The present study data were uploaded to the Gene Expression Omnibus website. The top 10 upregulated and downregulated DE genes (including mRNAs and lncRNAs) are listed in Tables II and III, respectively. Hierarchical cluster (Fig. 1), scatter plot (Fig. 2) and volcano plot (Fig. 3) analyses of the Table I. Quantitative PCR primer sequences.

| Gene     | Primer sequence, 5'-3' |
|----------|-----------------------|
| YIPF7    | AATAATGATTCATATGCTACGCCGA |
|          | ACAAGAACATCTCCTGGAGAC    |
| WNT9B    | GTGTGTTGGTGACACCTGAGT    |
|          | TGACACGGCATGAACTTGC      |
| TMEM255B | GCTTTGTGCCCTCCTGAATG     |
|          | AGGGCCTAGTGCGAGGAGGT     |
| P2RX4    | ATATTCCGTCTTGCGCAACAT    |
|          | CTCATATGGGTGCACTGCC      |
| GPR162   | F:TTGCGCTGGAAACCTTGTTG   |
|          | R:CTCAATGCCATTCTCCTGCCC  |
| CLSTN2   | TCAAGAACCAGCCTACAAAG     |
|          | AAGCAGTACCCAGGCTCATAAC   |
| AKR1B8   | CAGTTGAGCGACCGAGGAGATG   |
|          | CTGCGTCATAGGGAAACTCTT    |
| NILR1    | CCAAGGAGAAAGCGTTTATGC    |
|          | GGGTTTTACTTGGGCTATGCT    |
| AABR07007833.1 | GGTGTCACTACTCCTATCCTGCT |
|          | TCTCCTGCCTTTGGTCTTA      |
| AABR0701469.1 | TGTAGGAAGACTTAGAAGAATGC |
|          | AAGTGGTGGTGAATGCTGC      |
| AABR0705046.1 | CTGAGCAGGAAAGGCTCCTGTA |
|          | CTGGTGGAGGAGGACAGCTC     |
| AABR07058711.1 | TGCTCCATAAGTATCGAAGGCG |
|          | CAGATATGCGACCACAAACCTCA  |
| AABR07069067.1 | GCAGCTTCTTGACATCACATT   |
|          | A TAGGCAATTCCCTAGAGCATT  |
| AC125688.1 | CATTACATGACACTCTGTGCTG  |
|          | CGTGAGTCTCTGATCTTGTTA    |
| AABR07004428.1 | CACCCACGGAGATCCCACT     |
|          | GAGCCTCTCCCTGAGCTGTGTT  |
| β-ACTIN  | CGAGTACAACCTTCTTGCAGC    |
|          | ACCCATACCCACCATCACA      |

AKR1B8, Aldo-keto reductase family 1, member B8; CLSTN2, calystemin 2; GPR162, G protein-coupled receptor 162; NILR1, leukocyte immunoglobulin like receptor B2; P2RX4, purinergic receptor P2X 4; TMEM255B, transmembrane protein 225B; WNT9B, Wnt family member 9B; YIPF7, Yip1 domain family member 7.
DE genes are presented. Overall, there were 144 DE mRNAs and 63 DE lncRNAs in the VC group vs. the Control group, 63 DE mRNAs and 148 DE lncRNAs in the VC + MOP group vs. the VC group and 173 DE mRNAs and 54 DE lncRNAs in the VC + MOP group vs. the Control group. The most significantly upregulated DE genes in VC group vs. the

### Table II. Top 10 upregulated differentially expressed genes between groups by RNA-sequencing analysis.

#### A, VC vs. Control

| Tract ID          | Gene name   | Gene type       | Fold-change | P-value  |
|-------------------|-------------|-----------------|-------------|----------|
| ENSRNOG00000026336 | TMEM255B    | Protein-coding  | 7.72        | 6.9x10^{-4} |
| ENSRNOG00000006494 | TUBG2       | Protein coding  | 2.68        | 7.4x10^{-3} |
| ENSRNOG00000054954 | NILR1       | Protein coding  | 2.33        | 3.2x10^{-2} |
| ENSRNOG00000026497 | PIGC        | Protein coding  | 2.26        | 7.5x10^{-4} |
| ENSRNOG000000051890| LOC102549170| lncRNA          | 2.09        | 1.7x10^{-2} |
| ENSRNOG00000016143 | GPR162      | Protein coding  | 1.91        | 1.1x10^{-3} |
| ENSRNOG00000053415 | AABR07014649.1| lncRNA         | 1.74        | 1.2x10^{-2} |
| ENSRNOG00000058993 | AABR07062183.1| Protein coding| 1.70        | 9.7x10^{-3} |
| ENSRNOG00000002207 | GUF1        | Protein coding  | 1.69        | 3.7x10^{-2} |
| ENSRNOG00000052173 | RANBP3L     | Protein coding  | 1.61        | 1.4x10^{-3} |

#### B, VC + MOP vs. VC

| Tract ID          | Gene name   | Gene type       | Fold-change | P-value  |
|-------------------|-------------|-----------------|-------------|----------|
| ENSRNOG00000029401 | ACTG2       | Protein coding  | 3.04        | 3.0x10^{-2} |
| ENSRNOG00000017669 | CHD1L       | Protein coding  | 2.30        | 1.3x10^{-2} |
| ENSRNOG00000061865 | AABR07019334.1| lncRNA         | 2.05        | 5.3x10^{-3} |
| ENSRNOG00000060166 | AABR07069067.1| lncRNA         | 1.76        | 3.1x10^{-2} |
| ENSRNOG00000059729 | AC116236.2 | lncRNA          | 1.63        | 1.2x10^{-2} |
| ENSRNOG0000007335| CCL11       | Protein coding  | 1.58        | 3.2x10^{-2} |
| ENSRNOG00000057837 | AABR07017236.1| Protein coding| 1.57        | 8.9x10^{-3} |
| ENSRNOG00000057135 | AABR07070714.2| lncRNA         | 1.56        | 4.4x10^{-2} |
| ENSRNOG00000042665 | AABR0707130.2 | Protein coding| 1.56        | 2.8x10^{-2} |
| ENSRNOG00000052005 | AABR07028945.1| lncRNA         | 1.55        | 1.6x10^{-2} |

#### C, VC + MOP vs. Control

| Tract ID          | Gene name   | Gene type       | Fold-change | P-value  |
|-------------------|-------------|-----------------|-------------|----------|
| ENSRNOG00000043085 | CLSTN2      | Protein coding  | 2.11        | 2.4x10^{-2} |
| ENSRNOG00000023861 | SNAP91      | Protein coding  | 2.08        | 2.9x10^{-2} |
| ENSRNOG00000059602 | AABR07072984.1| lncRNA         | 1.73        | 4.5x10^{-2} |
| ENSRNOG00000059504 | AABR07015078.2| Protein coding| 1.67        | 2.9x10^{-2} |
| ENSRNOG00000052211 | AABR07058167.1| lncRNA         | 1.65        | 6.2x10^{-3} |
| ENSRNOG00000052668 | TCF24       | Protein coding  | 1.63        | 3.9x10^{-2} |
| ENSRNOG00000057070 | AABR07014350.1| lncRNA         | 1.63        | 5.4x10^{-3} |
| ENSRNOG00000034129 | AABR07061382.1| Protein coding| 1.51        | 4.5x10^{-2} |
| ENSRNOG00000023035 | SMIM8       | Protein coding  | 1.50        | 6.3x10^{-3} |
| ENSRNOG00000011969 | DOCK9       | Protein coding  | 1.48        | 1.2x10^{-4} |

lncRNA, long intragenic non-coding RNA; VC, varicocele; MOP, *Morinda officinalis* polysaccharide; TMEM255B, transmembrane protein 225B; TUBG2, tubulin γ-2 chain; NILR1, leukocyte immunoglobulin-like receptor B2; PIGC, phosphatidylinositol glycan anchor biosynthesis class C; GPR162, G protein-coupled receptor 162; GUF1, GUF1 homolog, GTPase; RANBP3L, RAN binding protein 3-like; ACTG2, Actin, g smooth muscle; CHD1L, chromodomain-helicase-DNA-binding protein 1-like; CCL11, C-C motif chemokine 11; CLSTN2, calsyntenin 2; SNAP91, Clathrin coat assembly protein AP180; TCF24, transcription Factor 24; SMIM8, small integral membrane protein 8.
Table III. Total of 10 downregulated differentially expressed genes between groups by RNA-sequencing analysis.

A, VC vs. Control

| Tract ID         | Gene name            | Gene type     | Fold-change | P-value    |
|------------------|----------------------|---------------|-------------|------------|
| ENSRNOG000000054630 | AABR07050146.1       | lincRNA       | 0.48        | 4.8x10^2   |
| ENSRNOG00000004517 | IGF1                 | Protein coding| 0.49        | 1.8x10^3   |
| ENSRNOG000000061865 | AABR07019334.1       | lincRNA       | 0.55        | 2.5x10^2   |
| ENSRNOG00000001300 | P2RX4                | Protein coding| 0.58        | 2.4x10^2   |
| ENSRNOG000000053160 | AABR07071659.2       | lincRNA       | 0.58        | 3.4x10^2   |
| ENSRNOG00000009734 | AABR07069067.1       | Protein coding| 0.80        | 9.2x10^3   |
| ENSRNOG00000006166 | AABR07069067.1       | lincRNA       | 0.62        | 9.9x10^3   |
| ENSRNOG000000020945 | MS4A1                | Protein coding| 0.63        | 3.7x10^2   |
| ENSRNOG000000060865 | AABR07013167.1       | lincRNA       | 0.64        | 4.4x10^2   |
| ENSRNOG000000056171 | AC105705.1           | lincRNA       | 0.64        | 5.0x10^2   |

B, VC + MOP vs. VC

| Tract ID         | Gene name            | Gene type     | Fold-change | P-value    |
|------------------|----------------------|---------------|-------------|------------|
| ENSRNOG00000002224 | YIPF7               | Protein coding| 0.47        | 1.9x10^2   |
| ENSRNOG00000002207 | GUF1                 | Protein coding| 0.48        | 1.9x10^2   |
| ENSRNOG000000026976 | VOM2R57             | Protein coding| 0.52        | 4.0x10^3   |
| ENSRNOG000000058242 | EPS8L3               | Protein coding| 0.59        | 1.8x10^2   |
| ENSRNOG000000048209 | EPS8L3               | Protein coding| 0.60        | 3.0x10^2   |
| ENSRNOG000000059026 | AABR07055885.1       | lincRNA       | 0.62        | 2.8x10^2   |
| ENSRNOG000000027142 | OOG1                 | Protein coding| 0.63        | 6.5x10^3   |
| ENSRNOG000000003409 | NEWGENE_156544       | Protein coding| 0.64        | 4.9x10^2   |
| ENSRNOG000000021010 | ARL2                 | Protein coding| 0.68        | 3.5x10^2   |
| ENSRNOG000000054516 | AABR07056680.1       | lincRNA       | 0.68        | 4.6x10^2   |

C, VC + MOP vs. Control

| Tract ID         | Gene name            | Gene type     | Fold-change | P-value    |
|------------------|----------------------|---------------|-------------|------------|
| ENSRNOG000000046897 | ATRX                | Protein coding| 0.41        | 4.0x10^3   |
| ENSRNOG000000008074 | CYP11A1              | Protein coding| 0.44        | 3.2x10^2   |
| ENSRNOG000000053160 | AABR07071659.2       | lincRNA       | 0.46        | 1.1x10^2   |
| ENSRNOG000000004517 | IGF1                 | Protein coding| 0.47        | 9.5x10^4   |
| ENSRNOG000000002079 | MAPK10               | Protein coding| 0.51        | 3.7x10^2   |
| ENSRNOG000000060545 | AC125688.1           | lincRNA       | 0.52        | 8.0x10^4   |
| ENSRNOG000000036641 | LOC689065            | protein coding| 0.53        | 2.6x10^2   |
| ENSRNOG000000061906 | AABR07024261.1       | protein coding| 0.54        | 2.0x10^2   |
| ENSRNOG000000057691 | AC112557.1           | lincRNA       | 0.58        | 7.7x10^4   |
| ENSRNOG000000009734 | AKR1B10              | protein coding| 0.58        | 1.1x10^2   |

lincRNA, long intragenic non-coding RNA; VC, varicocele; MOP, *Morinda officinalis* polysaccharide; IGF1, insulin-like growth factor; P2RX4, purinergic receptor P2X 4; MS4A1, membrane-spanning 4A1; YIPF7, Yip1 domain family member 7; GUF1, GUF1 homolog, GTPase; EPS8L3, epidermal growth factor receptor kinase substrate 8-like protein 3; OOG1, oogenesin 1; ARL2, ADP-ribosylation factor-like protein 2; ATRX, ATP-dependent helicase ATRX; CYP11A1, cholesterol side-chain cleavage enzyme.

Control group, VC + MOP group vs. the VC group, and VC + MOP group vs. the Control group were TMEM255B, actin g 2 smooth muscle and calsyntenin 2, respectively. The most significantly downregulated DE genes in VC group vs. the Control group, VC + MOP group vs. the VC group, and VC + MOP group vs. the Control group were AABR07050146.1, YIPF7 and ATP-dependent helicase ATRX chromatin remodeler, respectively.
GO and KEGG analyses of DE genes. To elucidate the functions of the DE genes, GO term enrichment and KEGG pathway analyses were performed. The GO functional annotations were classified into three categories: Molecular function, cellular components and biological processes. The top 10 enriched GO terms of DE genes, both upregulated and downregulated (Figs. 4 and 5) and the top 10 enriched KEGG pathways of DE genes, both upregulated and downregulated, (Fig. 6) are shown.

Co-expression network of the chosen DE mRNAs and IncRNAs. Correlation coefficients of selected DE mRNAs (protein-coding genes) and IncRNAs (non-protein-coding genes) were calculated to build a co-expression network (Pearson correlation coefficient ≥0.8; P≤0.05; false discovery rate, ≤1; Fig. 7). These DE mRNAs and IncRNAs presented in Fig. 7 were selected according to their function based on the GO term enrichment result, but not the total DE genes. The enriched DE genes were selected based on the GO terms...
the present study were interested in, such as the ‘response to steroid hormone’, ‘oxidation-reduction process’, ‘positive regulation of MAPK cascade’ and ‘DNA repair’ terms.

Validation of DE mRNAs and lncRNAs through RT-qPCR. The DE mRNAs and lncRNAs identified by RNA-Seq were validated using RT-qPCR. The results are presented in Table IV and Fig. 8. There were six DE mRNAs and four DE lncRNAs in the VC group vs. the Control group, one DE mRNA and four DE lncRNAs in the VC + MOP group vs. the VC group and four DE mRNAs and two DE lncRNAs in the VC + MOP group vs. the Control group. Varicocele and MOP treatment appeared to have opposing effects on the expression levels of YIPF7, AABR07007833.1, AABR07014649.1 and AABR07069067.1. To be specific, the varicocele increased the expression levels of YIPF7, AABR07007833.1 and AABR07014649.1, and decreased the expression level of AABR07069067.1, while MOP treatment reversed these changes.

Discussion

In our previous study, varicocele induced reproductive dysfunction in male rats via mechanisms such as destruction of the seminiferous epithelium and TJ structure, downregulation of TJ proteins (occludin, claudin-11 and zona occludens protein 1), deregulation of hormone levels and an increase in cytokine (TGF-β3 and TNF-α) levels. MOP repaired varicocele-induced damage and promoted spermatogenesis (the most effective dose was found to be 300 mg/kg) (17). However, the molecular mechanisms underlying the pathophysiology of varicocele and the therapeutic effect of MOP are still unknown. In the present study, mRNA and lncRNA sequencing analyses, combined with validation
of DE genes through RT-qPCR, were performed to bridge these data gaps.

According to GO results, the pathophysiology of varicocele may be associated with ‘epidermal growth factor receptor binding’, ‘ligand-gated calcium channel activity’, ‘growth factor receptor binding’, ‘histone kinase activity’ and ‘microtubule motor activity’. Notably, numerous DE genes between the VC and control groups were enriched in cancer-related pathways, such as the ‘p53 signaling pathway’, which is downregulated in breast cancer and melanoma; this warrants further research and validation.

According to the KEGG pathway analysis, ‘cytokine-cytokine receptor interaction’, ‘Wnt signaling pathway’ and ‘p53 signaling pathway’ were all implicated in the varicocele-therapeutic effect of MOP. In our previous study, the levels of TGF-β3 and TNF-α were upregulated in experimental rat left testicular tissue and downregulated following MOP treatment, potentially through the cytokine-cytokine receptor interaction pathway (17). The Wnt signaling pathway plays a notable role in the normal physiology and pathology of the male reproductive system. The Wnt/β-catenin pathway is involved in the annexin 5-mediated stimulation of testosterone synthesis (35), and its dysregulation is linked to the development of granulosa cell tumors in the testis (36). Additionally, the activation of Wnt/β-catenin signaling in Sertoli cells results in germ cell loss and seminiferous tubule degeneration (37). Moreover, the Wnt/β-catenin signaling pathway facilitates the proliferation of spermatogonial stem cells in the testis (38).
Figure 4. GO analysis of the top 10 DE genes between different groups, as ranked by their enrichment score. Top 10 (A) BP, (B) CC and (C) MF terms between the VC and control groups. Top 10 (D) BP, (E) CC and (F) MF terms between the VC + MOP and VC groups. Top 10 (G) BP, (H) CC and (I) MF terms between the VC + MOP and control groups. DE genes with fold-change >1.2 and P≤0.05 were used. BP, biological process; CC, cellular component; MF, molecular function; GO, Gene Ontology; DE, differentially expressed; Sig, significant; VC, varicocele; MOP, *Morinda officinalis* polysaccharide.
Thus, proper regulation of Wnt/β-catenin signaling is necessary for adult spermatogenesis, and its disruption may result in infertility (39). The results of the present study provide compelling evidence for the involvement of Wnt/β-catenin signaling...
in varicocele progression and the therapeutic effect of MOP in varicocele; this evidence is worthy of further research.

The RT-qPCR analysis revealed that one coding gene, \textit{YIPF7}, and three non-coding genes, \textit{AABR07007833.1}, \textit{AABR07014649.1} and \textit{AABR07069067.1}, were DE between the VC and Control groups, and between the VC + MOP and VC groups. Varicocele and MOP treatment appeared to have opposing effects on the expression of these genes, implying that these genes may play a role in varicocele pathophysiology and the repair effect of MOP. Specifically, varicocele increased the expression levels of \textit{YIPF7}, \textit{AABR07007833.1} and \textit{AABR07014649.1}, and decreased the expression level of \textit{AABR07069067.1}, while MOP treatment reversed these effects. The YIP1 family of proteins are involved in protein transport between the endoplasmic reticulum and Golgi apparatus (40), as well as the regulation of membrane dynamics (41). Decreasing the expression of \textit{YIPF7} enhances the intestinal inflammatory response and upregulates the \textit{TNF} mRNA.

Figure 6. Kyoto Encyclopedia of Genes and Genomes analysis of pathways corresponding to the top 10 differentially expressed genes between groups. (A) VC and control groups, (B) the VC + MOP and VC groups, and (C) the VC + MOP and control groups. Differentially expressed genes with fold-change >1.2 and P≤0.05 were used. VC, varicocele; MOP, \textit{Morinda officinalis} polysaccharide; DE, differentially expressed; Sig, significant.
The change in \textit{YIPF7} expression may be associated with the testicular inflammatory response and the fluctuation of the TNF-\(\alpha\) expression level induced by varicocele and MOP. This finding is in accordance with the results of our previous study; thus, we hypothesize that \textit{YIPF7} is involved in the process of varicocele development by increasing the TNF-\(\alpha\) level in the left testicular tissue, which MOP treatment is able to decrease (17). Due to the lack of extensive research on lncRNA, the functions of AABR07007833.1, AABR07014649.1 and AABR07069067.1 remain elusive. In the present study, according to the co-expression network analysis, these non-coding genes were positively associated with phosphatidylinositol glycan anchor biosynthesis class C insulin-like growth factor 1 (\textit{IGF1}), \textit{P2RX4}, \textit{TMEM255B} and \textit{WNT9B}, as well as others.

Aldo-keto reductase family 1, member B8 (\textit{AKR1B8}), leukocyte immunoglobulin-like receptor B2 (\textit{NILR1}), \textit{P2RX4}, \textit{TMEM255B} and \textit{WNT9B} were also DE between the VC and control groups. \textit{TMEM255B}, also known as \textit{FAM70B}, encodes the transmembrane protein 255b, which has been proposed as a prognostic marker for muscle-invasive bladder cancer (43). The expression level of \textit{TMEM255B} in the VC group was \textasciitilde63-fold higher compared with that of the control group. Such a large difference in expression levels suggests that \textit{TMEM255B} could be used as a novel diagnostic marker for varicocele; however, further clinical research is required to confirm this hypothesis. \textit{WNT9B} takes part in the Wnt/\(\beta\)-catenin signaling pathway, described as aforementioned. \textit{P2RX4}, also known as \textit{P2X4} or \textit{P2X4R}, encodes the ATP-gated \textit{P2RX4} ion channel. According to a previous study, extracellular ATP is a danger molecule for peritubular cells and aggravates inflammatory responses in the testis (44). \textit{P2RX4} is involved in pain processing (45-47), and its downregulation has been shown to moderate allergen-induced airway inflammation (48).
Although the function of P2RX4 in the male reproductive system is unclear, according to its diverse biological activities under physiological and pathological conditions (44-49), it is hypothesized that changes in P2RX4 expression levels are involved in varicocele pathogenesis via the stimulation of inflammatory responses and disruption of transmembrane ion channel function.

In the present study, RNA sequencing and RT-qPCR were performed on rat testicular tissue to reveal the molecular mechanisms underlying varicocele pathophysiology and the restorative effect of MOP on varicocele-induced damage in male reproductive systems. The results of GO and KEGG pathway enrichment analyses showed that ‘ligand-gated calcium channel activity’, ‘cytokine-cytokine receptor interaction’ and the ‘Wnt signaling pathway’ may all be implicated to underlie this effect. RT-qPCR confirmed that YIPF7 is upregulated in varicocele and downregulated by MOP. Based on its diverse biological activities and intimate connection to TNF-α, YIPF7 is considered a key mediator of varicocele pathogenesis and therapeutic effects of MOP. Furthermore, differential expression of AKR1B8, NILR1, P2RX4, TMEM255B and WNT9B was detected between the VC group and the control group. TMEM255B may be a potential novel diagnostic marker for varicocele; the role of WNT9B and P2RX4 in varicocele is possibly mediated by the activation of Wnt signaling and the regulation of transmembrane ion channels and the inflammatory response, respectively.

Table IV. Expression of differentially expressed genes by reverse transcription-quantitative PCR.

A, VC vs. Control

| Gene name       | Gene type   | Mean fold-change ± SD | P-value |
|-----------------|-------------|-----------------------|---------|
| AKR1B8          | Protein coding | 0.47±1.1x10^{-2}    | 0.024   |
| NILR1           | Protein coding | 2.98±6.2x10^{-4}    | 0.044   |
| P2RX4           | Protein coding | 0.48±4.1x10^{-3}    | 0.041   |
| TMEM255B        | Protein coding | 63.34±1.4x10^{-2}   | 0.044   |
| WNT9B           | Protein coding | 0.61±1.0x10^{-3}    | 0.026   |
| YIPF7           | Protein coding | 2.43±6.3x10^{-3}    | 0.031   |
| AABR07007833.1  | lincRNA     | 1.51±2.6x10^{-5}    | 0.033   |
| AABR07014649.1  | lincRNA     | 1.42±1.5x10^{-3}    | 0.025   |
| AABR07050146.1  | lincRNA     | 0.81±5.1x10^{-3}    | 0.035   |
| AABR07069067.1  | lincRNA     | 0.47±6.5x10^{-4}    | 0.014   |

B, VC + MOP vs. VC

| Gene name       | Gene type   | Mean fold-change ± SD | P-value |
|-----------------|-------------|-----------------------|---------|
| YIPF7           | Protein coding | 0.31±7.3x10^{-3}    | 0.025   |
| AABR07007833.1  | lincRNA     | 0.44±3.9x10^{-5}    | 0.0092  |
| AABR07014649.1  | lincRNA     | 0.77±1.0x10^{-3}    | 0.0011  |
| AABR07069067.1  | lincRNA     | 2.27±7.3x10^{-4}    | 0.0047  |
| AABR07004428.1  | lincRNA     | 0.52±1.4x10^{-3}    | 0.049   |

C, VC + MOP vs. Control

| Gene name       | Gene type   | Mean fold-change ± SD | P-value |
|-----------------|-------------|-----------------------|---------|
| AKR1B8          | Protein coding | 0.50±9.4x10^{-3}    | 0.0072  |
| CLSTN2          | Protein coding | 7.82±1.5x10^{-3}    | 0.023   |
| GPR162          | Protein coding | 1.49±2.0x10^{-4}    | 0.038   |
| WNT9B           | Protein coding | 0.58±1.1x10^{-3}    | 0.030   |
| AC125688.1      | lincRNA     | 0.54±3.0x10^{-2}    | 0.0022  |
| AABR07058711.1  | lincRNA     | 1.22±2.2x10^{-4}    | 0.040   |

lincRNA, long intragenic non-coding RNA; VC, varicocele; MOP, Morinda officinalis polysaccharide; AKR1B8, Aldo-keto reductase family 1, member B8; CLSTN2, calsyntenin 2; GPR162, G protein-coupled receptor 162; NILR1, leukocyte immunoglobulin like receptor B2; P2RX4, purinergic receptor P2X 4; TMEM255B, transmembrane protein 225B; WNT9B, Wnt family member 9B; YIPF7, Yip1 domain family member 7.
In summary, the present study provides a foundation for understanding the molecular basis of varicocele pathophysiology and the varicocele-therapeutic effect of MOP, offers insights into novel strategies for varicocele diagnosis and treatment, and suggests directions for further study.

Acknowledgements
Not applicable.

Funding
The present study was supported by The Training Program Foundation for the Talents of Health and Family Planning Commission in Fujian Province (grant no. 2018-1-74), The Start-up Foundation of Fujian Medical University (grant no. 2017XQ1005), The Research Foundation for High-Level Talents of Fujian Medical University (grant no. XRCZX2017033), The Natural Science Foundation of Fujian Province (grant no. 2017J01819) and The Co-construction Science Foundation of National Health and Family Planning Commission-Joint Program for Tackling Key Problems of Health and Education in Fujian Province (grant no. WKJ2016-2-35).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding authors upon reasonable request. The datasets generated and analyzed during the current study are available in the Gene Expression Omnibus repository, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi (accession no. GSE139447; secure token: sfaxocskhpxnix).

Authors’ contributions
LZ performed the experiments and the statistical analysis, and drafted the manuscript. WW and XZ conceived the study and participated in its design and coordination. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study was approved by The Animal Approval Committee of Fujian Medical University (approval no. SYXK-2012-0001).

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Leslie SW, Sajjad H and Siref LE: Varicocele. In: StatPearls. StatPearls Publishing, Treasure Island, FL, 2021.
2. Wang NN, Dallas K, Li S, Baker L and Eisenberg ML: The association between varicocoeles and vascular disease: An analysis of U.S. Claims data. Andrology 6: 99-103, 2018.
3. Reesink DJ, Huisman PM, Wiltink J, Kruger AE and Lock TM: Sneeze and pop: A ruptured varicocele; analysis of literature, guided by a well-documented case-report. BMC Urol 19: 14, 2019.
4. Sigalos JT and Pastuszak AW: Chronic orchialgia: Epidemiology, diagnosis and evaluation. Transl Androl Urol 6 (Suppl 1): S37-S43, 2017.
Afshar A, Aliaghaei A, Nazarian H, Abbaszadeh HA, Naserzadeh P, Fathabadi FF, Abdi S, Raei P, Aghajanpour F, Norouzian M and Abdolzadeh MA: Cumulative-loaded ion particle improvement of spermatogenesis in azoospermic mouse induced by long-term scrotal hyperthermia. Reprod Sci 28: 371-380, 2021.

Jarow JP: Effects of varicocele on male fertility. Hum Reprod Update 7: 59-64, 2001.

Mehta A and Goldstein M: Microsurgical varicocelectomy: A review. Asian J Androl 15: 56-60, 2013.

Ahlberg NE, Bartley O and Chidekel N: Right and left gonadal veins. An anatomical and statistical study. Acta Radiol Diagn (Stockh) 4: 593-601, 1966.

Bach PV, Najiari BB and Goldstein M: Varicocele-a case for early intervention. F1000Res 5: 1792, 2016.

Chiba K, Ramasamy R, Lamb DJ and Lipshultz LI: The varicocele: Diagnostic dilemmas, therapeutic approaches and future perspectives. Asian J Androl 18: 276-281, 2016.

Fretz PC and Sandlow JI: Varicocele: Current concepts in pathophysiology, diagnosis, and treatment. Urol Clin North Am 29: 921-937, 2002.

Luo DY, Yang G, Liu JJ, Yang YR and Dong Q: Effects of varicocele on testosterone, apoptosis and expression of STAR mRNA in rat Leydig cells. Asian J Androl 13: 287-291, 2011.

Saypol DC, Howards SS, Turner TT and Miller ED Jr: Influence of surgically induced varicocele on testicular blood flow, temperature and histology in adult rats and dogs. J Clin Invest 68: 39-45, 1981.

Pastuszak AW and Wang R: Varicocele and testicular function. Asian J Androl 17: 659-667, 2015.

Obzek E, Yurekli M, Soylu A, Damarci M and Balbay MD: The role of adrenomedullin in varicocele and impotence. BJU Int 86: 694-698, 2000.

Kim IT, Park HJ, Nam JH, Park YM, Won JH, Choi J, Choe BK and Lee KT: In-vitro and in-vivo anti-inflammatory and antinociceptive effects of the methanol extract of the roots of Morinda officinalis. J Pharm Pharmacol 57: 607-615, 2005.

Zhang L, Zhao X, Wang F, Lin Q and Wang W: Effects of morinda officinalis polysaccharide on experimental varicocele rats. Evid Based Complement Alternat Med 2016: 5365291, 2016.

Marinov GK: On the design and prospects of direct RNA sequencing. Brief Funct Genomics 16: 326-335, 2017.

Li X, Wu Z, Fu X and Han W: IncRNAs: Insights into their function and mechanisms in underlying disorders. Mutat Res Rev Mutat Res 762: 1-21, 2014.

Kazimierczak M, Kasprzowicz MK, Kasprzyk ME and Wrzesinski J: Human long noncoding RNA interactome: Detection, characterization and function. Int J Mol Sci 21: 3027, 2020.

Li L, Zhuang Y, Zhao X and Li X: Long non-coding RNA in neuronal development and neurological disorders. Front Genet 9: 744, 2018.

Hu Y, Lin J, Fang H, Fang J, Li C, Chen W, Liu S, Ondrejka S, Gong Z, Reu F, et al: Targeting the MALAT1/PARPi/LIG3 complex induces DNA damage and apoptosis in multiple myeloma. Leukemia 32: 2250-2262, 2018.

Mirza AH, Kaur S and Pociot F: Long non-coding RNAs as novel players in β cell function and type 1 diabetes. Hum Genomics 11: 17, 2017.

Zhang Y, Hou YM, Gao F, Xiao JW, Li CC and Tang Y: IncRNA GAS5 regulates myocardial infarction by targeting the mir-525-5p/CALM2 axis. J Cell Biochem 120: 18678-18688, 2019.

Meralando M and Fatica A: Alteration of epigenetic regulation by long noncoding RNAs in cancer. Int J Mol Sci 21: 570, 2018.

Yang Y, Junjie P, Sanjun C and Ma Y: Long non-coding RNAs in colorectal cancer: Progression and future directions. J Cancer 8: 2017.

Lalisse S, Hua J, Lenoir M, Linck N, Rassendren F and Ulmann L: Sensory neuronal P2RX4 receptors control BDNF signaling in testicular stromal cells causing granulosa cell tumor of the testis. Carcinogenesis 35: 869-878, 2009.

Kerr GE, Young JC, Horvay K, Abud HE and Loveland KL: Regulated Wnt/beta-catenin signaling sustains adult spermato genesis in mice. Biol Reprod 90: 3, 2014.

Kim SW, Jung YS, Ahn JB, Shin ES, Jang HW, Lee HJ, Kim T, Kim DY, Bang D, Kim WH and Cheon JH: Identification of genetic susceptibility loci for intestinal Behcet's disease. Sci Rep 7: 39850, 2017.

Kang HW, Yoon HY, Ha YS, Kim WT, Kim YJ, Yun SJ, Lee SC and Kim WH: FAM70B as a novel prognostic marker for cancer progression and cancer-specific death in muscle-invasive bladder cancer. Korean J Urol 53: 598-606, 2012.

Tamura D, Fleck D, Fröhlich T, von Eysmont H, Arnold GJ, Spehr J, Schwarzner JU, Köhn FM, Spehr M and Mayerhofer A: ATP-mediated events in peritubular cells contribute to sterile testicular inflammation. Sci Rep 8: 1431, 2018.

Jurgà AM, Piotrowska A, Makuch W, Przewlocka B and Mika J: Blockade of P2X4 receptors inhibits neuropathic pain-related behavior by preventing MMP-9 activation and, consequently, pronociceptive interleukin release in a rat model. Front Pharmacol 8: 48, 2017.

Tsuda M, Masuda T, Tozaki-Saitoh H and Inoue K: P2X4 receptors and neuropathic pain. Front Cell Neurosci 7: 191, 2013.

Lalisse S, Hua J, Lenoir M, Linck N, Rassendren F and Ulmann L: Sensory neuronal P2RX4 receptors control BDNF signaling in inflammatory pain. Sci Rep 8: 964, 2018.

Zech A, Wiesler B, Ayata CK, Schlaich T, Dürk T, Hößfeld M, Fathabadi FF, Abdi S, Raee P, Aghajanpour F, Norouzian M and Ehrat N, Cicko S and Idzko M: P2X4 deficiency in mice alleviates allergen-induced airway inflammation. OncoTarget 7: 80288-80297, 2016.

Sadowinick AD, Gu BJ, Trabousee AL, Bernalles CQ, Encarnacion M, Yee IM, Criscuoli MG, Huang X, Ou A, Milligan CJ, et al: Purinergic receptors P2RX4 and P2RX7 in familial multiple sclerosis. Hum Mutat 38: 736-744, 2017.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.